PDF(Pubmed)
Abstract：
BACKGROUND: The tripartite motif (TRIM) proteins have been reported to play crucial roles in various malignancies. However, the clinical significance of TRIM proteins in colorectal cancer (CRC) remains controversial. This study aimed to evaluate the association between TRIM proteins and the clinicopathological features and survival outcomes in patients with CRC.
METHODS: We performed a meta-analysis to investigate whether TRIM is a prognostic factor in CRC. PubMed, Embase, Web of Science, CNKI and Weipu databases were searched to identify eligible studies that evaluated the association between TRIM proteins and overall survival (OS), as well as the clinicopathological features of patients with CRC. Hazard ratios (HR) or odds ratios (OR) with 95% confidence interval (CI) were derived and pooled using a fixed-effects model.
RESULTS: From inception to March 2023, we extracted study characteristics and prognostic data for each identified study. Twelve studies enrolling 1608 patients were eligible for inclusion. Data on OS and recurrence-free survival (RFS) were available for 12 and 2 studies, respectively. The pooled analysis results showed a significant correlation between the elevated TRIM proteins and shorter OS (HR = 2.42, 95% CI: 1.96-2.99) and worse RFS (HR = 2.51, 95% CI: 1.78-3.54) in patients with CRC. The combined ORs indicated that TRIM protein over-expression was significantly associated with advanced TNM stage (OR = 2.26, 95% CI: 1.25-4.10), deep tumor invasion (OR = 2.01, 95% CI: 1.04-3.88), lymph node metastasis (OR = 2.99, 95% CI: 2.19-4.09) and perineural invasion (OR = 1.95, 95% CI: 1.18-3.23).
CONCLUSIONS: Our findings suggest that TRIM proteins can predict tumor progression and poor prognosis in CRC. Therefore, TRIM proteins may be promising therapeutic targets for patients with CRC.
METHODS: We performed a meta-analysis to investigate whether TRIM is a prognostic factor in CRC. PubMed, Embase, Web of Science, CNKI and Weipu databases were searched to identify eligible studies that evaluated the association between TRIM proteins and overall survival (OS), as well as the clinicopathological features of patients with CRC. Hazard ratios (HR) or odds ratios (OR) with 95% confidence interval (CI) were derived and pooled using a fixed-effects model.
RESULTS: From inception to March 2023, we extracted study characteristics and prognostic data for each identified study. Twelve studies enrolling 1608 patients were eligible for inclusion. Data on OS and recurrence-free survival (RFS) were available for 12 and 2 studies, respectively. The pooled analysis results showed a significant correlation between the elevated TRIM proteins and shorter OS (HR = 2.42, 95% CI: 1.96-2.99) and worse RFS (HR = 2.51, 95% CI: 1.78-3.54) in patients with CRC. The combined ORs indicated that TRIM protein over-expression was significantly associated with advanced TNM stage (OR = 2.26, 95% CI: 1.25-4.10), deep tumor invasion (OR = 2.01, 95% CI: 1.04-3.88), lymph node metastasis (OR = 2.99, 95% CI: 2.19-4.09) and perineural invasion (OR = 1.95, 95% CI: 1.18-3.23).
CONCLUSIONS: Our findings suggest that TRIM proteins can predict tumor progression and poor prognosis in CRC. Therefore, TRIM proteins may be promising therapeutic targets for patients with CRC.
摘要：
背景：据报道，三方基序（TRIM）蛋白在各种恶性肿瘤中起着至关重要的作用。然而,TRIM蛋白在结直肠癌(CRC)中的临床意义仍存在争议.本研究旨在评估TRIM蛋白与CRC患者临床病理特征和生存结果之间的关系。
方法：我们进行了一项荟萃分析，以研究TRIM是否是CRC的预后因素。PubMed,Embase,WebofScience,检索了CNKI和Weipu数据库，以确定评估TRIM蛋白与总生存期（OS）之间关联的合格研究。以及CRC患者的临床病理特征。使用固定效应模型得出具有95％置信区间（CI）的危险比（HR）或比值比（OR）并进行汇总。
结果：从开始到2023年3月，我们提取了每项确定研究的研究特征和预后数据。纳入1608名患者的12项研究符合纳入条件。12项和2项研究均可获得OS和无复发生存率（RFS）的数据，分别。合并分析结果显示，在CRC患者中，升高的TRIM蛋白与较短的OS（HR=2.42，95％CI：1.96-2.99）和较差的RFS（HR=2.51，95％CI：1.78-3.54）之间存在显着相关性。联合OR表明TRIM蛋白过表达与TNM分期进展显著相关(OR=2.26,95%CI:1.25-4.10),肿瘤深部浸润（OR=2.01，95%CI：1.04-3.88），淋巴结转移（OR=2.99，95％CI：2.19-4.09）和神经浸润（OR=1.95，95％CI：1.18-3.23）。
结论：我们的研究结果表明TRIM蛋白可以预测CRC的肿瘤进展和不良预后。因此,TRIM蛋白可能是CRC患者的有希望的治疗靶标。
方法：我们进行了一项荟萃分析，以研究TRIM是否是CRC的预后因素。PubMed,Embase,WebofScience,检索了CNKI和Weipu数据库，以确定评估TRIM蛋白与总生存期（OS）之间关联的合格研究。以及CRC患者的临床病理特征。使用固定效应模型得出具有95％置信区间（CI）的危险比（HR）或比值比（OR）并进行汇总。
结果：从开始到2023年3月，我们提取了每项确定研究的研究特征和预后数据。纳入1608名患者的12项研究符合纳入条件。12项和2项研究均可获得OS和无复发生存率（RFS）的数据，分别。合并分析结果显示，在CRC患者中，升高的TRIM蛋白与较短的OS（HR=2.42，95％CI：1.96-2.99）和较差的RFS（HR=2.51，95％CI：1.78-3.54）之间存在显着相关性。联合OR表明TRIM蛋白过表达与TNM分期进展显著相关(OR=2.26,95%CI:1.25-4.10),肿瘤深部浸润（OR=2.01，95%CI：1.04-3.88），淋巴结转移（OR=2.99，95％CI：2.19-4.09）和神经浸润（OR=1.95，95％CI：1.18-3.23）。
结论：我们的研究结果表明TRIM蛋白可以预测CRC的肿瘤进展和不良预后。因此,TRIM蛋白可能是CRC患者的有希望的治疗靶标。
